Free Trial
LON:CEL

Celadon Pharmaceuticals (CEL) Share Price, News & Analysis

Celadon Pharmaceuticals logo
GBX 5 +0.50 (+11.11%)
As of 05/30/2025 09:51 AM Eastern

About Celadon Pharmaceuticals Stock (LON:CEL)

Key Stats

Today's Range
4
5
50-Day Range
3
9.60
52-Week Range
2.21
100
Volume
16,737 shs
Average Volume
244,404 shs
Market Capitalization
£3.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder. For further information please visit our website www.celadonpharma.com

Receive CEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CEL Stock News Headlines

Celadon Pharmaceuticals faces potential administration
Big Oil’s big pivot
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.
Celadon Pharmaceuticals to Delist From AIM
See More Headlines

CEL Stock Analysis - Frequently Asked Questions

Celadon Pharmaceuticals' stock was trading at GBX 14 at the start of the year. Since then, CEL stock has decreased by 64.3% and is now trading at GBX 5.
View the best growth stocks for 2025 here
.

Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Celadon Pharmaceuticals investors own include AutoZone (AZO), Bahamas Petroleum (BPC), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM).

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Communication
Current Symbol
LON:CEL
CIK
N/A
Fax
N/A
Employees
2,780
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-£4.97 million
Net Margins
-4,024.62%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£123,381.65
Cash Flow
GBX 1.64 per share
Price / Cash Flow
3.05
Book Value
GBX 3.80 per share
Price / Book
1.32

Miscellaneous

Free Float
N/A
Market Cap
£3.07 million
Optionable
Not Optionable
Beta
-0.26
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (LON:CEL) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners